Tag Archive for: oncology

Poolbeg Pharma plc – Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

/in

Former Amryt team’s arrival supports increasing focus upon Rare and Orphan Diseases 12 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that independent research[i] [ii] conducted on behalf of Poolbeg confirms a >$10 billion market opportunity […]

Read more

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

/in

Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million) London, UK, 1 February 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B […]

Read more

Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

/in

Market opportunity estimated to be greater than US$1 billion Key highlights –      Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model –      Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS –      Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced […]

Read more

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

/in

Berlin, Germany, 10th January 2024 – Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces it has submitted an application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to undertake a Phase 1 trial of 123I-ATT001, its Iodine-123 labelled PARP inhibitor in patients with recurrent […]

Read more

HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration

/in

Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION Therapeutics ApS (‘HERVOLUTION’), a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer. Robert Coleman PhD, MBA, has over 12 […]

Read more